These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11571697)

  • 1. Cerebrospinal fluid markers in children with cerebral white matter abnormalities.
    Kristjánsdóttir R; Uvebrant P; Lekman A; Månsson JE
    Neuropediatrics; 2001 Aug; 32(4):176-82. PubMed ID: 11571697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of children with cerebral white matter abnormalities.
    Kristjánsdóttir R; Uvebrant P; Wiklund LM
    Eur J Paediatr Neurol; 2000; 4(1):17-26. PubMed ID: 10701100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial fibrillary acidic protein and neurofilament in children with cerebral white matter abnormalities.
    Kristjánsdóttir R; Uvebrant P; Rosengren L
    Neuropediatrics; 2001 Dec; 32(6):307-12. PubMed ID: 11870586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The axonal damage marker tau protein in the cerebrospinal fluid is increased in patients with acute encephalopathy with biphasic seizures and late reduced diffusion.
    Tanuma N; Miyata R; Kumada S; Kubota M; Takanashi J; Okumura A; Hamano S; Hayashi M
    Brain Dev; 2010 Jun; 32(6):435-9. PubMed ID: 19679415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gangliosides and sulfatide in cerebrospinal fluid in leukoaraiosis.
    Tarvonen-Schröder S; Blennow K; Lekman A; Fredman P; Räihä I; Sourander L
    Dement Geriatr Cogn Disord; 1997; 8(3):174-9. PubMed ID: 9137896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype.
    Wallin A; Blennow K; Rosengren L
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S102-5. PubMed ID: 10609688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Level of tau protein in children treated for acute lymphoblastic leukemia.
    Muszyńska-Rosłan K; Krawczuk-Rybak M; Protas PT; Hołownia A
    Pediatr Neurol; 2006 May; 34(5):367-71. PubMed ID: 16647996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ophthalmological abnormalities in children with cerebral white matter disorders.
    Kristjánsdóttir R; Sjöström A; Uvebrant P
    Eur J Paediatr Neurol; 2002; 6(1):25-33. PubMed ID: 11993953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral lipid and protein abnormalities in Menkes' steely-hair disease.
    Hara A; Taketomi T
    Jpn J Exp Med; 1986 Dec; 56(6):277-84. PubMed ID: 3599492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of gangliosides and sulfatide in human cerebrospinal fluid with a microimmunoaffinity technique.
    Davidsson P; Fredman P; Månsson JE; Svennerholm L
    Clin Chim Acta; 1991 Mar; 197(2):105-15. PubMed ID: 2049855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new procedure for determining ganglioside GD3 a potential glial cell activation marker in cerebrospinal fluid.
    Lekman A; Fredman P
    Neurochem Int; 1998 Aug; 33(2):103-8. PubMed ID: 9761454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery.
    Shiiya N; Kunihara T; Miyatake T; Matsuzaki K; Yasuda K
    Ann Thorac Surg; 2004 Jun; 77(6):2034-8. PubMed ID: 15172260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early reduction of total N-acetyl-aspartate-compounds in patients with classical vanishing white matter disease. A long-term follow-up MRS study.
    Dreha-Kulaczewski SF; Dechent P; Finsterbusch J; Brockmann K; Gärtner J; Frahm J; Hanefeld FA
    Pediatr Res; 2008 Apr; 63(4):444-9. PubMed ID: 18356755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers of damage of the central nervous system in multiple sclerosis.
    Bartosik-Psujek H; Stelmasiak Z
    Ann Univ Mariae Curie Sklodowska Med; 2001; 56():389-92. PubMed ID: 11977345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
    de Bont JM; Vanderstichele H; Reddingius RE; Pieters R; van Gool SW
    Eur J Paediatr Neurol; 2008 Jul; 12(4):334-41. PubMed ID: 17951083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated nerve growth factor levels in cerebrospinal fluid associated with progressive cortical atrophy.
    Suzaki I; Hara T; Tanaka C; Dejima S; Takeshita K
    Neuropediatrics; 1997 Oct; 28(5):268-71. PubMed ID: 9413006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted MR of the brain: methodology and clinical application.
    Mascalchi M; Filippi M; Floris R; Fonda C; Gasparotti R; Villari N
    Radiol Med; 2005 Mar; 109(3):155-97. PubMed ID: 15775887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.
    Agren-Wilsson A; Lekman A; Sjöberg W; Rosengren L; Blennow K; Bergenheim AT; Malm J
    Acta Neurol Scand; 2007 Nov; 116(5):333-9. PubMed ID: 17922727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aicardi-Goutières syndrome: differential diagnosis and aetiopathogenesis.
    Lanzi G; D'Arrigo S; Drumbl G; Uggetti C; Fazzi E
    Funct Neurol; 2003; 18(2):71-5. PubMed ID: 12911136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis.
    Teunissen CE; Dijkstra CD; Jasperse B; Barkhof F; Vanderstichele H; Vanmechelen E; Polman CH; Bö L
    Neuropathol Appl Neurobiol; 2006 Jun; 32(3):318-31. PubMed ID: 16640650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.